

GA-map IBS dysbiosis test, 1/14

January 2014—Norwegian molecular diagnostics company Genetic Analysis has launched its GA-map IBS Dysbiosis Test. The DNA-based test makes it possible to effectively and routinely analyze the composition of the gut microbiota (bacteria profile) and any dysbiosis.

The GA-map IBS Dysbiosis Test can be run in any molecular diagnostics laboratory. Target DNA is first isolated from patient stool samples. Then conserved regions of the bacterial 16S rRNA gene are used as templates to amplify the more variable regions in-between that are unique for different bacteria. The final result is based on the patient's microbiota profile and an algorithm specifically made for assessing dysbiosis in IBS patients.

The test will be rolled out in Europe, followed by a U.S. FDA application in early 2015, according to a statement from the company's CEO, Kari Stenersen.

[**Genetic Analysis**](#), +44(0) 7711821527